Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
Cabaletta Bio presented encouraging clinical and translational data for its autologous CAR T cell therapy rese-cel at the ASGCT 2026 Annual Meeting. The data showed that the lowest dose of preconditioning-free rese-cel produced compelling drug-free responses in half of treated refractory patients with pemphigus vulgaris over six months. Additionall…